194 results about "Bone marrow suppression" patented technology

The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.

The invention relates to methods for treating and preventing radiation and / or chemotherapy related injury and / or afflictions, such as myelosuppression and decreased macrophage activity, by administering a prophylactically or therapeutically effective amount of particulate, bioavailable β(1,3; 1,6) glucan. The invention also relates to methods in which β(1,3; 1,6) glucan is provided in the form of whole glucan particles, microparticulate β-glucan particles or a combination thereof.

The invention discloses application of dihydromyricetin in preparing a medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor. In particular, the application is to prepare medicines for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, preventing and treating arrest of bone marrow and baldness, resisting mutation, preventing and treating the generation of secondary tumors, preventing and treating tumor transfer, and preventing and treating breast cancer, cervical carcinoma, intestinal cancer and the like. The invention creatively finds that the dihydromyricetin has the effects of removing free radicals, inhibiting reaction chains of the free radicals, resisting the mutation, inhibiting the expression of the tumor gene, causing the death of tumor cells, preventing and treating the tumor generation, preventing and treating the secondary tumors and the transfer of the secondary tumors and preventing and treating infection. Therefore, as the medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, the dihydromyricetin can inhibit and alleviate chemical damage, prevent and treat damage of a mutagen and further prevent gene mutation or the secondary tumors; and by combination with the radiotherapy and chemotherapy, the effects of preventing untoward reactions in radiotherapy and chemotherapy of tumor and preventing generation of tumors are achieved.

The present invention relates to novel myeloid suppressor cells (MSCs) and to methods of isolating these MSCs are also included. The MSCs of the present invention can be used to treat or prevent autoimmune diseases or alloimmune responses. The MSCs of the present invention may also be used to reduce a T cell response, induce T regulatory cells, and produce T cell tolerance.

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

The invention discloses a food therapy preparation for resisting the suppression of bone marrow after lung cancer chemotherapy. The food therapy preparation is prepared from the following components according to parts by weight: 20-30 parts of astragalus root, 10-15 parts of radix codonopsis pilosulae, 10-15 parts of angelica, 10-20 parts of glossy privet fruit, 10-20 parts of Chinese wolfberry, 20-30 parts of spatholobus stem, 6-9 parts of villous anomum, 6-10 parts of tangerine peel and 100-200 parts of crucian. By the clinical application of many years, the total effective rate of the invention is 96.29%, the acting rate is 81.48%, the effective rate is 14.81%, and the invention has safety and high efficiency. The invention is a pure traditional Chinese medicine food therapy formula, has convenient taking and no toxic or side effect and has the advantages of small toxic or side effect, good curative effect, low cost and the like.

The invention provides a novel application of a fullerene and / or metallic fullerene micro-nano material. The novel application is that of the fullerene and / or metallic fullerene micro-nano material in the preparation of drugs or drug carriers having at least one property as in 1) to 5): 1), preventing and / or treating bone marrow suppression; 2), clearing free radicals; 3), enriching bone marrow; 4), preventing and / or treating at least one of leukocyte decrease, platelet decrease, hemoglobin decrease and monocyte decrease caused by bone marrow suppression; 5), protecting bone marrow cells and / or hematopoietic cells. The fullerene and / or metallic fullerene micro-nano material is simple and quick to prepare, is good in biocompatibility and highly rich in bone marrow area, has certain residence time, can also be finally discharged out of the body by metabolism, has no evident cytotoxicity on bone marrow cells and normal cells and is safe and nontoxic. The fullerene and / or metallic fullerene micro-nano material has a promising application prospect as a protectant for bone marrow suppression caused by chemotherapy.

The invention discloses a fullerene micro-nano material with effects of prevention and / or treatment on myelosuppression and a use thereof. The novel use of the fullerene micro-nano material comprises use of the fullerene and / or metallofullerene micro-nano material in a drug or a drug carrier with at least one of properties such as 1, prevention and / or treatment on myelosuppression, 2, prevention and / or treatment on at least one of myelosuppression-caused leucopenia, platelet decreasing, hemoglobin decreasing and monocyte decreasing, and 3, protection of liver tissue, spleen tissue and kidney tissue. The myelosuppression is caused through tumor radiation therapy or rays producing myelosuppression side effects. The fullerene and / or metallofullerene micro-nano material can prevent and treat myelosuppression and prevent liver, spleen and kidney damage.

The invention discloses a phospholipid complex albumin nanoparticle containing epipodophyllotoxins medicine. The nanoparticle contains a complex formed by epipodophyllotoxins medicine and phospholipid and albumin. The nanoparticle comprises the following raw materials in parts by weight: 1 part of epipodophyllotoxins medicine, 1-50 parts of phospholipid and 2-100 parts of albumin. The phospholipid complex albumin nanoparticle can be used for remarkably reducing the toxicity of the epipodophyllotoxins medicine, especially bone marrow suppression; meanwhile, the phospholipid complex albumin nanoparticle has liver-lung targeting property.

The invention relates to an application of dimethyldiguanide in drugs taking protective effect on chemoradiotherapy injury. As an optimal implementation scheme, the invention relates to the application of the dimethyldiguanide in preparing drugs taking protective effect on long-term bone marrow suppression caused by radiotherapy. As an optimal implementation scheme, the invention relates to the application of the dimethyldiguanide in preparing drugs taking protective effect on the long-term bone marrow suppression caused by chemotherapeutics. Proved by the invention, the dimethyldiguanide has a certain protective effect on hematopoietic immune cell injury caused by irradiation and / or the chemotherapeutics.

The present invention relates to a method of use involving the administration of the herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, to mammalian animals undergoing cancer treatments that would induce the bone marrow suppression side effect, such as chemotherapy and radiation therapy. The composition can take on the form of an oil capsule, tablets, pills, and pastes etc. to be administered orally at specific dosages. The composition can also take on the form of an injection to be administered intravenously and intraperitoneally at specific dosages. The administration can be made before and or after the cancer treatment.

Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.

The invention provides a pharmaceutical composition for treating thrombocytopenia, which comprises gen-seng, epimeddium, radix astragali, angelica sinensis, radix rehmanniae preparata, spatholobus stems, hairyvein agrimony, and tangerine peel. The pharmaceutical composition of the invention can be prepared into clinically-acceptable dosage forms by adding routine auxiliary materials according to routine technology. The pharmaceutical composition of the invention has significant effect on treating thrombocytopenia and leucopenia, promoting proliferation of bone marrow hematopoietic stem cells, repairing damage and injury of bone marrow hematopoietic tissue caused by radiation, preventing marrow inhibition caused by radiotherapy and chemotherapy, or improving symptoms and increasing life quality of tumor patients, and has no side effect.

The invention discloses a medicine for promoting leukopoiesis, which can be prepared into any one of conventional solid oral preparations by using milk vetch, deerhorn glue, American ginseng, epimedium, angelica, sealwort, eclipta, medlar, fructus psoraleae and spatholobus stem as raw medicines and using conventional methods of traditional Chinese medicine preparations. The medicine disclosed by the invention has the functions of strengthening the spleen and nourishing the kidney, nourishing qi and blood and tonifying yin and yang, can be used for regulating the bone marrow haematopoietic function after radiotherapy and chemotherapy and promoting the leukopoiesis, and is suitable for preventing and treating bone marrow suppression leukopenia after radiotherapy and chemotherapy. The clinical test research shows that the total effective rate of the leukopoiesis is 88.46%.

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

The invention provides a protopanoxadiol submicroemulsion preparation and a preparation method thereof. The protopanoxadiol submicroemulsion preparation comprises protopanoxadiol, oil, an emulsifier and a co-emulsifier, average particle size of the protopanoxadiol submicroemulsion preparation is 110-130nm, and Zeta potential ranges from -40mV to -20mV. The invention also provides an application of the protopanoxadiol submicroemulsion preparation in preparation of a medicine with the effects of promoting hematopoietic cell proliferation and alleviating bone marrow inhibiting effect caused by tumour treatment.

The invention relates to a dammarane aglycon compound and application thereof, in particular to application of oral administration and injection preparations which are prepared by a single dammarane aglycon compound prepared by basic hydrolysis by utilizing the particular patent technology of the Pegasus Pharmaceuticals Group of Canada by adopting Asian ginseng stem and leave saponin or prepared in the way that the dammarane aglycon compound is matched with other medically permissive auxiliary materials in prevention and treatment on bone marrow suppression caused by different chemotherapy and radiotherapy.

The invention provides, in part, compositions and methods for protecting a hemopoietic cell, or for treating myelosuppression, in a subject in need thereof, by administering an effective amount of an inhibitor of a SH2-containing inositol-5′-phosphatase.

The invention relates to novel medical application of anhydroicaritin, particularly to application of anhydroicaritin in preparing a drug for treating or preventing thrombopenia, and belongs to the field of medicines. In order to overcome the technical defects that, in the prior art, the thrombopenia therapeutic drug is unabiding in therapeutic effect, high in possibility of recidivation during drug discontinuance and high in side effect, the invention provides a therapeutic drug containing anhydroicaritin. The therapeutic drug can greatly improve the platelet level of a parent when being used for treating thrombopenia, particularly immune thrombopenia, and has an obvious therapeutic effect; the therapeutic drug further has the obvious therapeutic effect on treating thrombopenia caused by myelosuppression; when being used for treating thrombopenia, anhydroicaritin has the advantages of being obvious in curative effect, low in treatment cost and little in toxic and side effects, and the therapeutic drug is quite suitable for clinical popularization and application.

The present invention relates to application of Podocarpus macrophyllus fruit polysaccharide in preparation of a medicament for preventing and treating liver cancer or a health food. The Podocarpus macrophyllus fruit polysaccharide is obtained by taking fruits of Podocarpus plants in Podocarpaceae, that is, Podocarpus macrophyllus(Thunb.)D. Don or Podocarpus macrophyllus(Thunb.)D. Don var. maki(Sieb.)Endl. as raw materials, and conducting water extraction, protein removal and column chromatography purification. The Podocarpus macrophyllus fruit polysaccharide has a significant inhibitory effect on tumor growth of liver cancer-bearing mice. The Podocarpus macrophyllus fruit polysaccharide can be made into capsules, oral liquids or granules after appropriate pharmaceutical adjuvants in a certain proportion are added. When used in prevention and treatment of liver cancer, the Podocarpus macrophyllus fruit polysaccharide has no toxic and side effects such as nausea, vomiting, alopecia andmyelosuppression and other common effects in cytotoxic antitumor drug, and is a purely natural safe effective plant polysaccharide.

The invention discloses an anti-tumor compound extracted from a house lizard, as well as a preparation method of the anti-tumor compound extracted from the house lizard and application of the compound as antitumor drugs. In clinical application, the anti-tumor compound extracted from the house lizard can be dissolved with normal saline and then used in an injection way or can be prepared into preparation for oral use directly; the anti-tumor compound extracted from the house lizard can be used for the chemotherapy of gastric cancer, lung cancer, liver cancer, colon cancer, breast cancer, leucocythemia, genital system tumors, and other common malignant tumors, plays remarkable anti-tumor effect without bone marrow suppression or damage to important organs under conventional dosage; and in addition, since the anti-tumor compound extracted from the house lizard can increase T cellular immunity, the anti-tumor compound has good Aids resistance.

The invention discloses a Chinese medicinal composition for raising leucocytes, which is mainly prepared from the following raw material medicaments of Radix Astragali and polygonatum rhizome according to weight ratio being 1:1-2:1. The invention discloses a traditional Chinese medicine for raising leucocytes, the active components are a Radix Astragali extract product and a polygonatum rhizome extract product, wherein the Radix Astragali extract product is at least a Radix Astragali polysaccharide extract product, and the polygonatum rhizome extract product is at least a polygonatum rhizome polysaccharide extract product; and the weight ratio of the Radix Astragali polysaccharide extract product to the polygonatum rhizome polysaccharide extract product is 1:1-3:1. The invention also discloses a preparation method and an application of the Chinese medicinal composition for raising leucocytes. The Chinese medicinal composition for raising leucocytes promote the differentiation propagation of the leucocytes and bone marrow cells, raising the leucocytes of the chemicotherapy patients, preventing and controlling marrow suppression of chemoradiotherapy, and improving Chinese medicinal symptoms and living quality of patients with cancer; for the patients with qi deficiency, through supplementing qi and nourishing Yin, the immunity is enhanced for improving the recovery of the patients with qi deficiency, and no toxic and side effects can be generated.

The invention discloses a micro-nano material for preventing and / or treating myelosuppression and application thereof. A fullerene and / or metal fullerene micro-nano material can be applied to preparing medicine with at least one of the following properties of preventing and / or treating myelosuppression, removing free radicals, preventing and / or treating at least one of leukocyte reduction, platelet reduction, hemoglobin reduction and monocyte reduction caused by myelosuppression, preventing bone marrow cells and / or hematopoietic cells, improving the function of antioxidant systems of organisms and protecting liver tissue, spleen tissue and kidney tissue. The fullerene and / or metal fullerene micro-nano material can be metabolized out of organisms, is enriched in visceral organs and marrow through blood circulation after intragastric administration or intraperitoneal injection, has an excellent function of preventing myelosuppression induced by chemotherapy in bodies, can effectively reduce toxic and side effects of chemotherapy on marrow and other organs, and is still obvious in protection effect after multiple treatment courses.

The present invention provides a novel polypeptide possessing growth activities on hematopoietic stem cells, a gene encoding the polypeptide and an antibody reacting specifically with the polypeptide, as well as a method for isolating the above gene and a vector for use in the method. According to the present invention, it is possible to elucidate the pathogenesis of various hematopoietic diseases due to abnormalities in hematopoietic stem cells and of bone marrow inhibition, and to diagnose and treat such diseases. According to the present invention, it is also possible to amplify hematopoietic stem cells in vitro for bone marrow transplantation necessary for the treatment of such diseases or improve efficiency of a gene transfer into hematopoietic stem cells for utilizing the gene therapy. The vector and the method of gene isolation developed to isolate the SCGF gene of the invention are applicable to search for other novel genes and able to contribute to the technological progress in genetic engineering.

The invention discloses a Chinese medicinal composition for raising leucocytes, which is mainly prepared from the following raw material medicaments in part by weight: 6 to 60 parts of astragalus, 6 to 60 parts of Siberian solomonseal rhizome, 6 to 60 parts of Mongolian snakegourd root and 3 to 30 parts of epimedium herb. The invention also discloses a method for preparing the Chinese medicinal composition and application thereof in preparation of a medicament for treating leucopenia, improving immune function of an organism, promoting proliferation of marrow hematopoietic stem / progenitor cells, protecting hemopoietic microenvironment, repairing the damage and harm to marrow hematopoietic tissues by radioactive rays, preventing and controlling marrow suppression of chemoradiotherapy, promoting colony formation of granulocytes and monocytes, improving Chinese medicinal symptoms and living quality of patients with cancer, or promoting the recovery of patients with Qi-Yin deficiency.

The invention relates to a traditional Chinese medicine preparation for preventing and treating bone marrow suppression after radiotherapy and chemotherapy. The traditional Chinese medicine preparation is prepared from, by weight, 10-20 parts of codonopsis pilosula, 15-60 parts of astragali radix, 15-20 parts of fructus ligustri lucidi, 10-20 parts of eclipta alba, 15-30 parts of caulis spatholobi, 10-30 parts of peanut coat, 10-20 parts of rhizoma polygonati, 6-10 parts of ginger and 10-15 parts of radix bupleuri. The traditional Chinese medicine preparation has the advantages of good curative effect and low cost, has the curative effect similar to GM-CsF on the aspect of leukopenia (including severe bone marrow suppression) after radiotherapy and chemotherapy, can improve the clinical symptoms, has no obvious side effect, and meanwhile can effectively improve blood platelet and hemoglobin values and effectively prevent adverse consequences, such as serious infection and fever caused by leukocyte decrease.